Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance immunotherapy after clinical benefit from prior therapy in metastatic melanoma
2008-006366-29Phase 3Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Jul 2009
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of aldesleukin, isotretinoin, peginterferon alfa-2b in melanoma, sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Started Jul 2009; status: terminated.
02
Drugs
aldesleukinisotretinoinpeginterferon alfa-2b
03
Conditions
melanoma
Beyond the preview
Go deeper on 2008-006366-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006366-29.